JAKARTA – For 27 years, Stimuno has been an integral part of the health journey for Indonesian families. Since its debut in 1999, this natural immunomodulator medication has accompanied families across generations, helping maintain strong immune systems so the body is better prepared to face various health challenges. Stimuno’s long journey is a testament to its consistency in delivering products tailored to family needs, earning lasting trust through uncompromised quality standards.
Public trust in Stimuno stems from the company’s commitment to scientific rigor. Stimuno is the first and only natural immunomodulator medication in Indonesia to receive Phytopharmaca (Fitofarmaka) status from the Indonesian Food and Drug Authority (BPOM), a milestone achieved in 2005. Made from green meniran leaves (Phyllanthus niruri), this Integrative Natural Modern Medicine (OMAI) has undergone rigorous testing, including preclinical trials, toxicity and safety testing, mechanism-of-action studies, efficacy trials, and clinical trials across various hospitals in Indonesia.
Prof. Raymond Tjandrawinata, Business Development and Scientific Affairs Director of PT Dexa Medica, stated that Stimuno has undergone clinical trials for seven diseases: acute respiratory tract infections, influenza-like illnesses, tuberculosis, hepatitis B, herpes zoster, varicella infection, and vaginal candidiasis.
“Through clinical trials across these seven conditions, Stimuno has proven to be an effective herb-based immunomodulator derived from meniran that works directly on the immune system to restore and improve immune function. Body immunity acts as a primary defense against infection, especially during pandemics and times when disease transmission risks are high,” explained Prof. Raymond.
Spanning nearly three decades, Stimuno’s journey is reflected in the enduring trust of its consumers. Stimuno has secured the Top Brand Award in the Children’s Supplement category for 17 consecutive years, underscoring consistent public trust in Stimuno as a top choice for children’s health.
Stimuno’s “School Health Day” Program
Mr. Andy Mitra Gunadi, General Manager of Consumer Health Division (CHD) at PT Dexa Medica, shared that to maintain close connections with consumers—particularly families and the younger generation—Stimuno consistently delivers health education through the “School Health Day” program. This initiative brings Stimuno closer to children and school environments while promoting early awareness about immune health. The program also engages parents through parenting seminars themed “Imun Kuat, Prestasi Hebat” (Strong Immunity, Great Achievements), ensuring comprehensive educational coverage.
“Through direct interaction and relevant daily health education for children and families, Stimuno builds a relationship that goes beyond the product itself. We aim to foster healthy lifestyle habits starting from school age and emphasize the importance of immune health for the whole family to sustain everyday productivity,” said Mr. Andy.
This strong trust has also propelled Stimuno into international markets. Developed and manufactured in Indonesia, the product is now exported to the Philippines, Nigeria, and Cambodia, expanding the reach of Indonesian natural medicine innovation to global communities.
As it enters its 27th year, Stimuno continues to grow alongside the evolving immune health needs of Indonesian families. Grounded in scientific proof, consumer trust, educational outreach, and an expanding global footprint, Stimuno remains deeply relevant after nearly three decades of service.